Udit Verma, MD
Hematology & Oncology · Dallas, TXNPI 1033178165
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (60.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 68.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $5,480 and has fallen 99.6% since, to $20 in 2025.
Across 15 payments — averaging $533.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$5K
- Exelixis Inc.$2K
- AstraZeneca$437
- Sanofi$350
- Pharmacyclics LLC, An Abbvie Company$96
- GSK$20
Across 111 payments — averaging $1661.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$161K
- Novartis$24K
What the payments were for
- Consulting fees$4,80060%
- Speaking & faculty fees$1,97025%
- Travel & lodging$81610%
- Food & beverage$4165%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $5,480 |
| Exelixis Inc. | 1 | $1,620 |
| AstraZeneca(2 entities) | 3 | $437 |
| Sanofi | 1 | $350 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $96 |
| GSK | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,002 in reported general payments places this provider in the 65th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 22 | $8,471 |
| Ondansetron Hcl | 33 | $3,832 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $596 |
| Ondansetron OdtOndansetron | 13 | $259 |
| Promethazine Hcl | 26 | $203 |
| Potassium Chloride | 17 | $187 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $165 |
| Mirtazapine | 18 | $78 |
| Furosemide | 14 | $15 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.